Asahi Kasei Kogyo Kabushiki Kaisha

Dainippon Pharmaceutical Company, Limited

Hiroshi Hayashi

Takao Kiyota

Mitsuru Shibukawa

Torao Ishida

Minoru Akiyama

Yoshio Sakurai

Shuichi Sugawara

Daikichi Nishimura

Shigeru Tsukagoshi

Kazuyoshi Hori

Masanobu Komiya

Takashi Shirai

Hajimu Sakamoto

Junji Kuwashima

Junichi Kajihara

Yoshiki Otsuka

Yukiji Shimojima

A pharmaceutical composition and its use in the treatment of cerebral edema are provided wherein the composition comprises an atrial natriuretic peptide having an amino acid sequence of 28 amino acids and at least one pharmaceutically acceptable carrier, diluent or excipient.

Treatment of cerebral edema with ANP pharmaceutical compositions

A pharmaceutical composition and a method for its use in the treatment of severe chronic inflammatory diseases, such as demyelinating disease, uveitis and graft-versus-host disease are provided. The composition comprises tumor necrosis factor as an active ingredient and at least one pharmaceutically acceptable carrier, diluent or excipient.

Methods for the treatment of demyelinating disease, uveitis, or

An aqueous solution containing a physiologically active substance, which is produced by recombinant DNA technique and which has cytotoxic activity against L-M cells and is capable of inducing hemorrhagic necrosis of transplanted Meth A sarcoma in the BALB/c mouse, can be effectively, efficiently purified by column chromatography using a column packed with a dye-bonded crosslinked agarose gel.

Method for purifying a physiologically active substance produced by

A protein having a polypeptide subunit containing an N-terminal amino acid sequence of Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gl n-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu. The protein of the present invention is obtained in substantially pure form at high activity recovery, and is excellent in inducing necrosis of tumors with no toxicity upon the normal tissues of the living body. The protein of the present invention is thermally stable and, therefore, when preparation of pharmaceutical compositions is conducted, the protein of the present invention can be stably formulated into compositions.

Protein having antitumor activity

A method for stabilizing Tumor Necrosis Factor (TNF), which comprises adding a stabilizing agent selected from a nonionic surfactant, at least one substance selected from the group consisting of D-glucose, D-galactose, D-xylose, D-glucuronic acid, a salt of D-glucuronic acid, trehalose, a dextran and a hydroxyethyl starch, and mixtures thereof to an aqueous solution or powder containing TNF, and a stable aqueous solution or powder which contains TNF and an effective amount of such a stabilizing agent selected from a nonionic surfactant, a specific sugar or sugar-related compound and mixtures thereof. The aqueous solution or powder containing TNF can be stored for a prolonged period of time without losing its activity, and is stable on freezing, thawing, lyophilization, heat-treatment or the like.

Method for stabilizing Tumor Necrosis Factor and a stable aqueous

A method for stabilizing a Tumor Necrosis Factor (TNF), which comprises adding at least one member selected from the group consisting of an albumin, a gelatin, a globulin, a protamine and a salt of protamine to an aqueous solution or powder containing TNF, and a stable aqueous solution or powder which contains TNF and an effective amount of such a protein. The aqueous solution or powder containing TNF can be stored for a prolonged period of time without losing its activity, and is stable on freezing, thawing, lyophilization or the like.

Method for stabilizing a tumor necrosis factor and a stable aqueous

A dried, sterilized column containing a carrier-fixed .gamma.-globulin capable of specifically combining with various harmful substances found in blood of patients suffering from certain diseases and acting as an antibody. The .gamma.-globulin fixed column according to the present invention has a prolonged storage stability, and an excellent activity and safety even after the storage for a prolonged period of time as compared with unsterilized columns. Therefore, the .gamma.-globulin fixed column according to the present invention may be advantageously used for medical instrument applications.

Dried, sterilized, gamma-globulin-fixed column and a process for

AI-77 compounds, pharmaceutically acceptable salts thereof, and a process for the preparation thereof are described, said compounds having the formulae ##STR1## wherein: X is NR.sub.6 or O; Y is NHR.sub.5 or combine with Z to provide a link for bonding C and C; Z is H or combines with Y to provide a link for bonding C and C; R.sub.1, R.sub.3 and R.sub.5 are each H, R', --CH.sub.2 R, or --COR; R.sub.6 is H or R; R.sub.7 is H, R or CH.sub.2 R; R is a hydrocarbon group consisting of a saturated or unsaturated straight or branched aliphatic group of C.sub.1 to C.sub.17, an aromatic group of C.sub.6 to C.sub.10, a cage type group of C.sub.7 to C.sub.10, a monocyclic aliphatic group of C.sub.3 to C.sub.8, an aromatic-aliphatic group of C.sub.7 to C.sub.15, a heterocyclic hydrocarbon of C.sub.1 to C.sub.9, wherein the above hydrocarbons can be substituted with one or more groups selected from halogen, oxo, carboxyl, hydroxyl, a saturated or unsaturated straight or branched aliphatic group of C.sub.1 to C.sub.5, an aromatic group of C.sub.6 to C.sub.10, a monocyclic aliphatic group of C.sub.3 to C.sub.8, an aromatic-aliphatic group of C.sub.7 to C.sub.11, alkoxy of C.sub.1 to C.sub.5, thioalkoxyl of C.sub.1 to C.sub.5, carboalkoxyl of C.sub.1 to C.sub.6, acyl of C.sub.1 to C.sub.5, acyloxy of C.sub.2 to C.sub.6 and a heterocyclic group of C.sub.1 to C.sub.9 ; R' is the same as R exclusive of those groups wherein unsaturated carbon or tertiary carbon is directly bonded to O or N; R.sub.2 is H, or combines with T.sub.1 to provide a link for bonding C and O in a lactone ring; T.sub.1 is OH or combines with R.sub.2 to provide a link for bonding C and O in a lactone ring; R.sub.4 is H or combines with T.sub.2 to provide a link for bonding C and O in a lactone ring; and T.sub.2 is OH or combines with R.sub.4 to provide a link for bonding C and O in a lactone ring; and pharmaceutically acceptable salts thereof.

AI-77 Compounds and pharmaceutically acceptable salts thereof

Compounds represented by formula (I) ##STR1## wherein one of Z.sub.1 ', Z.sub.2 ', Z.sub.3 ' and Z.sub.4 ' represents R, another one of Z.sub.1 ', Z.sub.2 ', Z.sub.3 ' and Z.sub.4 ' represents Z, and the remaining two moieties of Z.sub.1 ', Z.sub.2 ', Z.sub.3 ' and Z.sub.4 ' represents a hydrogen atom and/or a protective group, one of R and Z represents A.sub.1 and the other represents A.sub.2, A.sub.1 being an acyl group having 14 to 22 carbon atoms which does not contain a carboxylic group and A.sub.2 being an acyl group having 2 to 14 carbon atoms and having one carboxyl group, X represents a hydrogen atom or a halogen atom (hereinafter referred to as Compound Ia); a 2,2'-anhydro product of Compound Ia wherein Z.sub.2 ' represents a hydrogen atom (hereinafter referred to as Compound Ib); an arabinosylation product of Compound Ia (hereinafter referred to as Compound Ic); a deamination product of Compound Ia (hereinafter referred to as Compound Id); a 2'-deoxy product of Compound Id wherein Z.sub.2 ' represents a hydrogen atom (hereinafter referred to as Compound Ie); a salt of Compound Ia, Ib, Ic, or Id or Ie having an A.sub.2 group with a base (hereinafter referred to as Compound If); and a salt of Compound Ia, Ib or Ic wherein Z.sub.1 ' represents a hydrogen atom with an acid (hereinafter referred to as Compound Ih); and processes for preparing the same.

Growing community of inventors

Fuji, Japan

Hiroshi Hayashi